Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of GBR 830 in healthy volunteers
NL-OMON41093Phase 1Active, not recruiting
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of telazorlimab in autoimmune disease (4 arms), sponsored by Glenmark Pharmaceuticals. Started Sep 2014; status: active, not recruiting.
02
Drugs
telazorlimab
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON41093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41093.